Although we did not find a significant correlation between MAP4K5 mRNA and CSE2 mRNA in TCGA population (data not shown), our findings suggest that loss of MAP4K5 may be involved in chemotherapy resistance of pancreatic cancer, especially to regimens that contain irinotecan in the backbone. Here, MAP4K5 is linked to familial pancreatic carcinoma.